Group 1 - The core point of the announcement is the approval of the expected daily related transactions for the year 2025 by the company's supervisory board [1] - The related transactions involve the sale of pharmaceuticals and provision of production and research services to a related party, Hunan Hengchang Pharmaceutical Group Co., Ltd., by the company and its subsidiaries [1] - The transaction prices are based on market prices for similar businesses and are determined through friendly negotiations, ensuring fairness and reasonableness without adversely affecting the company's operations or harming the interests of minority shareholders [1] Group 2 - The supervisory board meeting was conducted in accordance with the Company Law and the company's articles of association, with all three participating supervisors voting in favor of the proposal [1] - The resolution received unanimous support with 3 votes in favor, 0 votes against, and 0 abstentions [1]